Full Breakdown
Otsuka Launches Global Early-Access Program for Ulefnersen in FUS-ALS
By Drooid · · How we work
Program Overview
Otsuka Pharmaceutical Development & Commercialization, Inc. announced a global early-access program (EAP) that allows eligible patients with a confirmed genetic diagnosis of FUS-ALS to receive ulefnersen, an investigational RNA-targeted therapy. The program is intended for individuals who cannot enroll in an ongoing clinical trial and meet predefined eligibility criteria. Requests must be submitted by a treating physician through Otsuka’s Early Access Portal; the company does not accept direct patient inquiries. After review, additional regulatory, ethics and site-readiness steps may be required before treatment can begin, and timing will vary.
FUS-ALS Background
FUS-ALS is a rare, genetically defined subtype of amyotrophic lateral sclerosis caused by pathogenic variants in the fused in sarcoma (FUS) gene. It accounts for an estimated 0.6 % of all ALS cases, but represents 43 %– 52 % of juvenile and pediatric ALS cases. The disease often progresses rapidly, leading to respiratory failure and death within 1–2 years of symptom onset in early-onset patients. No therapies currently target the underlying genetic cause.
Official Statements & Responses
The company emphasized that ulefnersen remains investigational and has not received approval from the U.S. Food and Drug Administration (FDA) or any other regulatory authority.
Data & Statistics
- FUS-ALS prevalence: 0.6 % of all ALS cases; 43 %– 52 % of juvenile ALS cases.
- Ulefnersen is being evaluated in the global Phase 1–3 FUSION trial (NCT04768972).
- The drug has received Fast Track designation for FUS-ALS and Orphan designation for ALS from the U.S. FDA, the European Medicines Agency and Swissmedic.
Verbatim Quotes
- “Our approach to early access for ulefnersen is guided by an assessment of the available clinical evidence and our commitment to patient safety,” — John Kraus
How to Access
Treating physicians can review eligibility criteria and submit applications via the Otsuka Early Access Portal. Approval depends on regulatory and ethics reviews, treatment-center readiness and patient-specific requirements, with variable timing from application to treatment.